title: Association of p53 Arg72Pro and MDM2 SNP309  polymorphisms with glioma.
abstract: Epidemiological studies of the association of variants p53 Arg72Pro and MDM2 single-nucleotide polymorphism 309 (SNP309)  with glioma risk have produced inconsistent results. The aim of the current  study was to evaluate the association of these 2 variants with glioma  susceptibility using a meta-analysis approach. For p53 Arg72Pro, 10  case-control studies including 2587 glioma patients and 4061 unrelated controls  were identified. The pooled odds ratios (ORs) for Arg/Pro heterozygotes and  Pro/Pro homozygotes were 1.08 [95% confidence interval (95%CI) = 0.85-1.37] and  1.08 (95%CI = 0.85-1.36), respectively, when compared to Arg/Arg carriers.  Under the dominant effect model, Pro allele carriers also showed no  significantly elevated glioma risk (pooled OR = 1.11, 95%CI = 0.90-1.38), and  similar results were found under the recessive-effect model (pooled OR = 1.17,  95%CI = 0.85-1.61). For variant MDM2 SNP309, 3 case-control studies  including 606 cases and 309 controls were identified. A marginal association  with glioma risk was found for heterozygous G/T carriers (pooled OR = 1.95,  95%CI = 1.00- 3.81), whereas homozygous G/G carriers showed an increased but  not significantly elevated risk of glioma (pooled OR = 2.14, 95%CI = 0.71-6.45)  compared with that of T/T homozygotes. We also found no significant association  between the MDM2 SNP309 polymorphism and glioma risk (pooled OR = 1.86,  95%CI = 0.94-3.67 and pooled OR = 1.25, 95%CI = 0.62-2.56, respectively) under  the dominant and recessive models. Taken together, the current data suggested  that the 2 polymorphisms may not contribute to glioma susceptibility.
authors.affiliation: Operation Room, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiaotong University, Shanghai, P.R. China.
authors.forename: J N
authors.initials: JN
authors.lastname: Zhang
authors.forename: S H
authors.initials: SH
authors.lastname: Yi
authors.forename: X H
authors.initials: XH
authors.lastname: Zhang
authors.forename: X Y
authors.initials: XY
authors.lastname: Liu
authors.forename: Q
authors.initials: Q
authors.lastname: Mao
authors.forename: S Q
authors.initials: SQ
authors.lastname: Li
authors.forename: W H
authors.initials: WH
authors.lastname: Xiong
authors.forename: Y M
authors.initials: YM
authors.lastname: Qiu
authors.forename: T
authors.initials: T
authors.lastname: Chen
authors.forename: J W
authors.initials: JW
authors.lastname: Ge
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics*; D015179:Colorectal Neoplasms / Q000235:genetics; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005910:Glioma / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics*; D012307:Risk Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2